Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies.

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Gilead Sciences, US Government Settle Patent Case Over HIV Prevention Drugs By Blake Brittain (Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over ...